You are here

  • Home
  • Archive
  • Volume 11, Issue 12
  • ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3

Article info

Article menu

This article has a correction. Please see:

Basic tumor immunology
Original research
ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3

Authors

  • Yong-Qiang Ao Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, ChinaCancer Center, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China PubMed articlesGoogle scholar articles
  • Jian Gao Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, ChinaCancer Center, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China PubMed articlesGoogle scholar articles
  • Chun Jin Department of Thoracic Surgery, Changhai Hospital, Naval Medical University, Shanghai, China PubMed articlesGoogle scholar articles
  • Shuai Wang Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, ChinaCancer Center, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China PubMed articlesGoogle scholar articles
  • Li-Cheng Zhang School of Basic Medical Sciences, Fudan University, Shanghai, China PubMed articlesGoogle scholar articles
  • Jie Deng Institute of Vascular Disease, Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Zong-wei Chen Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, ChinaCancer Center, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China PubMed articlesGoogle scholar articles
  • Hai-Kun Wang CAS Key Laboratory of Molecular Virology and Immunology, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Beijing, China PubMed articlesGoogle scholar articles
  • Jia-Hao Jiang Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, ChinaCancer Center, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China PubMed articlesGoogle scholar articles
  • Jian-Yong Ding Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, ChinaCancer Center, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China PubMed articlesGoogle scholar articles

Citation

Ao Y, Gao J, Jin C, et al
ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3
Journal for ImmunoTherapy of Cancer 2023;11:e007766. doi: 10.1136/jitc-2023-007766
Online issue publication 
December 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.